Condition: Adenocarcinoma - GEJ · Gastric Adenocarcinoma · Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
This phase II study will evaluate dostarlimab with a watch-and-wait approach for patients with localized mismatch repair deficiency (dMMR)/microsatellite instability (MSI) gastric or oeso-gastric junction adenocarcinoma. The goal of the study is to determine whether the surgery could be avoided in patients with localized dMMR/MSI-H gastric/OGJ adenocarcinoma with complete response at endoscopy and biopsies free of tumoral cells after treatment with dostarlimab, with a watch-and-wait approaches.
This description comes directly from the study's public registry record.
Marie-Line GARCIA LARNICOL, MD · +33 (01) 40 20 85 00 · gercor@gercor.com.fr
Always discuss trial participation with your own doctor first.
| CHRU Lille | Lille, France | Recruiting |
| Hôpital Saint Antoine | Paris, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06059495